中国卒中杂志 ›› 2018, Vol. 13 ›› Issue (05): 483-488.DOI: 10.3969/j.issn.1673-5765.2018.05.014

• 专题综述 • 上一篇    下一篇

高危非致残性缺血性脑血管事件的循证医学治疗

马琳,陈玮琪,荆京,王拥军,王伊龙   

  1. 100050 北京首都医科大学附属北京天坛医院神经病学中心;国家神经系统疾病临床医学研究中心
  • 收稿日期:2018-01-09 出版日期:2018-05-20 发布日期:2018-05-20
  • 通讯作者: 王伊龙 yilong528@gmail.com

Evidence-based Treatment of High Risk Non-Disabling Ischemic Cerebrovascular Events

  • Received:2018-01-09 Online:2018-05-20 Published:2018-05-20

摘要:

高危非致残性缺血性脑血管事件(high r isk n on-disabling ischemic cerebrovascular events, HR-NICE)具有发病率高、复发率高等特点,国内外指南均建议对HR-NICE人群进行快速评估、早期干 预以及建立专病管理系统等综合管理。同时在治疗方面,多项研究探讨了不同抗血小板药物治疗HRNICE 人群及针对不同病因的患者采用抗凝或溶栓治疗的有效性及安全性。本文就高危非致残性缺 血性脑血管事件的管理和治疗的循证医学证据作一简要综述。

文章导读: 本文对高危非致残性缺血性脑血管事件人群的综合管理和药物治疗进行了系统回顾,详细叙述了其循证医学证据。

关键词: 高危非致残性脑血管事件; 综合管理系统; 抗栓; 二级预防; 溶栓

Abstract:

The incidence and recurrence rate of high risk of disabling ischemic cerebrovascular events (HR-NICE) are high. The guidelines of both home and abroad suggest that the early comprehensive evaluation, intervention and establishing NICE management system will obtain great benefit. Several studies have revealed the efficacy and safety of antiplatelet medication, and choosing anticoagulation or thrombolysis treatment according to different cause, which may improve the prognosis. This article briefly reviews the evidence-based medicine in management of HR-NICE.

Key words: High risk non-disabling ischemic cerebrovascular events; Comprehensive management system; Antithrombotic therapy; Secondary prevention; Thrombolysis